Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Light Chain Amyloidosis and Non-Hodgkin's Lymphomas: A Peculiar Association with Distinct Clinical Features and Outcome

Marco Basset, MD, Irene Defrancesco, MD, Paolo Milani, MD, Sara Rattotti, MD, Andrea Foli, MD, Marzia Varettoni, MD, Alessandro Corso, MD, Marco Paulli, Giampaolo Merlini, MD, Luca Arcaini, MD, Giovanni Palladini, MDPhD

Blood (2018) 132 (Supplement 1): 2026.

https://doi.org/10.1182/blood-2018-99-118161

Published: 2018

Journal Articles

Pomalidomide + Bortezomib + Low-Dose Dexamethasone Vs Bortezomib + Low-Dose Dexamethasone As Second-Line Treatment in Patients with Lenalidomide-Pretreated Multiple Myeloma: A Subgroup Analysis of the Phase 3 Optimismm Trial

Meletios A Dimopoulos, MD, Katja Weisel, MD, Philippe Moreau, Larry Anderson, MD PhD, Darrell J White, MD, Jesus F San-Miguel, MD PhD, Pieter Sonneveld, MD PhD, Monika Engelhardt, MD, Matthew W Jenner, Alessandro Corso, MD, Jan Dürig, Michel Pavic, MD, Morten Salomo, Xin Yu, Tuong Vi Nguyen, Amine Bensmaine, Teresa Peluso, Mohamed Zaki, MD PhD, Paul Richardson

Blood (2018) 132 (Supplement 1): 3278.

https://doi.org/10.1182/blood-2018-99-111869

Published: 2018

Journal Articles

Bortezomib/Cyclophosphamide/Dexamethasone Versus Lenalidomide/Cyclophosphamide/Dexamethasone in Multiple Myeloma Patients at First Relapse: Final Results of a Phase III Study

Vittorio Montefusco, MD, Alessandro Corso, MD, Monica Galli, MD PhD, Elena Tagliabue, Sara Pezzatti, Francesca Patriarca, MD, Filippo Gherlinzoni, MD, Renato Zambello, MD, Simona Sammassimo, Magda Marcatti, MD, Andrea Nozza, Claudia Crippa, MD, Anna Maria Cafro, MD, Luca Baldini, Paolo Corradini, MD

Blood (2017) 130 (Supplement 1): 836.

https://doi.org/10.1182/blood.V130.Suppl_1.836.836

Published: 2017

Journal Articles

Biomarker-Based Screening of Organ Dysfunction in Patients with MGUS Allows Early Diagnosis of AL Amyloidosis

Giovanni Palladini, MDPhD, Marco Basset, MD, Paolo Milani, MD, Marzia Varettoni, MD, Silvia Mangiacavalli, MD, Francesca Russo, MD, Andrea Foli, MD, Alessandro Corso, MD, Giampaolo Merlini, MD

Blood (2017) 130 (Supplement 1): 1760.

https://doi.org/10.1182/blood.V130.Suppl_1.1760.1760

Published: 2017

Journal Articles

Real Life, Retrospective Analysis of Bortezomib Re-Use As Second Treatment for Relapsed Multiple Myeloma Patients Previously Exposed to Bortezomib-Based Therapies As First Line: The Rebound Study

Blood (2016) 128 (22): 4494.

https://doi.org/10.1182/blood.V128.22.4494.4494

Published: 2016

Journal Articles

VD Versus VTD Induction: Similar Efficacy in Controlling Disease in Transplant Eligible Multiple Myeloma Patients Outside Clinical Trials

Federica Cocito, MD, Silvia Mangiacavalli, MD, Virginia Valeria Ferretti, PhD, Claudio Salvatore Cartia, MD, Maya Ganzetti, Mario Cazzola, MD, Alessandro Corso, MD

Blood (2016) 128 (22): 5711.

https://doi.org/10.1182/blood.V128.22.5711.5711

Published: 2016

Journal Articles

Impact of Switching from Intravenous to Subcutaneous Bortezomib in Real Life. Overlapping Toxicity and Efficacy in All Settings of Myeloma Patients Balancing Schedule and Way of Bortezomib Adminisration

Silvia Mangiacavalli, MD, Federica Cocito, MD, Virginia Valeria Ferretti, PhD, Claudio Salvatore Cartia, MD, Maya Ganzetti, MD, Mario Cazzola, MD, Alessandro Corso, MD

Blood (2016) 128 (22): 5695.

https://doi.org/10.1182/blood.V128.22.5695.5695

Published: 2016

Journal Articles

Analysis of Final Data from the Multinational, Non-Interventional, Observational Emmos Study (NCT01241396) in Patients (Pts) with Multiple Myeloma (MM) in Real-World Clinical Practice

Blood (2015) 126 (23): 3034.

https://doi.org/10.1182/blood.V126.23.3034.3034

Published: 2015

Journal Articles

Treated Multiple Myeloma Patients: Demographic Characteristics, Incidence Rate and Mortality in Lombardy during the 2003-2009 Period

Paolo Corradini, MD, Alessandro Corso, MD, Lorenzo Giovanni Mantovani, Monica Galli, MD, Anna Maria Cafro, MD, Roberta Ciampichini, Paolo Cozzolino, Virginio Chiodini, Claudia Crippa, MD, Giuseppe Rossi, Giancarlo Cesana, Enrica Morra, MD

Blood (2014) 124 (21): 1329.

https://doi.org/10.1182/blood.V124.21.1329.1329

Published: 2014

Journal Articles

High Prevalence Of Extramedullary Relapse In Patients With Multiple Myeloma Treated With Novel Biological Agents

Silvia Mangiacavalli, MD, Alessandra Pompa, MD, Cristiana Pascutto, PhD, Virginia Ferretti, DR, Lara Pochintesta, MD, Federica Cocito, MD, Marzia Varettoni, Mario Lazzarino, Prof, Mario Cazzola, MD, Alessandro Corso, MD

Blood (2013) 122 (21): 1896.

https://doi.org/10.1182/blood.V122.21.1896.1896

Published: 2013

Journal Articles

Bendamustine, Low-Dose Dexamethasone, and Lenalidomide (BdL) For The Treatment Of Patients With Relapsed Multiple Myeloma Confirms Very Promising Results In a Phase I/II Study

Samantha Pozzi, MD, Stefania Badiali, MS, Alessandro Corso, MD, Pellegrino Musto, MD, Attilio Guarini, MD, Carla Minoia, MD, Donatella Vincelli, MD, Roberto Ria, MD, Luciano Masini, MD, Giovanni Quarta, MD, Massimo Gentile, MD, Carla Mazzone, MD, Antonio Palumbo, MD, Fortunato Morabito, MD, Stefano Sacchi, MD

Blood (2013) 122 (21): 3212.

https://doi.org/10.1182/blood.V122.21.3212.3212

Published: 2013

Journal Articles

Physician-Patient Relationship: Intervention Opportunities for Multiple Myeloma patients' Needs

Maria Felicia Pelagalli, PhD, Francesca Romana Dolcetti, Tommaso Caravita, MD, Maria Cantonetti, MD, Chiara Nozzoli, MD, Mario Boccadoro, MD, Luca Baldini, MD, Felicetto Ferrara, MD, Alessandro Corso, MD, Rita Rizzi, MD, Maria Teresa Petrucci, MD

Blood (2010) 116 (21): 2564.

https://doi.org/10.1182/blood.V116.21.2564.2564

Published: 2010

Journal Articles

Fotemustine IN COMBINATION with BORTEZOMIB and DEXAMETHASONE: Encouraging PRELIMINARY RESULTS FROM A PHASE II STUDY On Relapsed REFRACTORY MYELOMA PATIENTS

Alessandro Corso, MD, Silvia Mangiacavalli, MD, Federica Cocito, MD, Cristiana Pascutto, Cesare Astori, MD, Marzia Varettoni, MD, Ester Orlandi, MD, Patrizia Zappasodi, MD, Silvia Rizzi, MD, Ilaria Ambaglio, MD, Mario Lazzarino, Prof, Mario Cazzola, MD

Blood (2010) 116 (21): 3037.

https://doi.org/10.1182/blood.V116.21.3037.3037

Published: 2010

Journal Articles

Changing Pattern of Presentation in Monoclonal Gammopathy of Undetermined Significance: A Study on 1400 Cases

Marzia Varettoni, MD, Gian Matteo Pica, MD, Federica Cocito, Silvia Mangiacavalli, Cristiana Pascutto, Mario Lazzarino, MD, Alessandro Corso, MD

Blood (2008) 112 (11): 2706.

https://doi.org/10.1182/blood.V112.11.2706.2706

Published: 2008

Journal Articles

Has the Incidence of Extramedullary Disease Changed with the New Therapeutic Approaches? Analysis of a Cohort of 965 Multiple Myeloma (MM) Patients (pts).

Marzia Varettoni, MD, Alessandro Corso, MD, Gianmatteo Pica, MD, Patrizia Zappasodi, MD, Silvia Mangiacavalli, MD, Cristiana Pascutto, Mario Lazzarino

Blood (2007) 110 (11): 4749.

https://doi.org/10.1182/blood.V110.11.4749.4749

Published: 2007

Journal Articles

Low Efficacy of Thalidomide in Improving Response after Induction in Myeloma Patients Candidate to High-Dose Therapy.

Alessandro Corso, MD, Silvia Mangiacavalli, MD, Luciana Barbarano, MD, Patrizia Zappasodi, MD, Luciano Banfi, MD, Luigi Montalbetti, MD, Antonio Mazzone, MD, Sergio Fava, MD, Guido Frigerio, MD, Luciano Isa, MD, Sergio Montanara, MD, Daniele Perego, MD, Maria Savarè, MD, Lilj Uziel, MD, Alessandro Vismara, MD, Leonardo Campiotti, MD, Mario Fiumanò, MD, Mario Lazzarino, MD, Enrica Morra, MD

Blood (2006) 108 (11): 3567.

https://doi.org/10.1182/blood.V108.11.3567.3567

Published: 2006

Journal Articles

Bisphosphonates and Osteonecrosis of the Jaw: Advantages of a New Schedule.

Patrizia Zappasodi, MD, Alessandro Corso, MD, Marzia Varettoni, MD, Catherine Klersy, MD, Gianmatteo Pica, MD, Silvia Mangiacavalli, MD, Mario Lazzarino, MD

Blood (2006) 108 (11): 3590.

https://doi.org/10.1182/blood.V108.11.3590.3590

Published: 2006

Journal Articles

Modification of Cytokine Levels and CD34+ Stem Cell Adhesion Molecules during Mobilization in Multiple Myeloma (MM) Patients.

Patrizia Zappasodi, MD, Alessandro Corso, MD, Chiara Rusconi, MD, Mara De Amici, Erica Consensi, Cristiana Pascutto, Marzia Varettoni, MD, Silvia Mangiacavalli, MD, Gianmatteo Pica, MD, Mario Lazzarino, MD

Blood (2005) 106 (11): 5068.

https://doi.org/10.1182/blood.V106.11.5068.5068

Published: 2005

Journal Articles

High Dose Chemotherapy and Autologous Stem Cell Transplantation in Multiple Myeloma: Comparison of Four Preparative Regimens.

Emilio P. Alessandrino, MD, Letizia Zenone Bragotti, MD, Anna A. Colombo, MD, Alessandra Algarotti, MD, Paolo Bernasconi, MD, Margherita Maffioli, MD, Daniela Caldera, MD, Alessandro Corso, MD, Elisa Rumi, MD, Daniela Troletti, PhD, Mario Lazzarino

Blood (2005) 106 (11): 5489.

https://doi.org/10.1182/blood.V106.11.5489.5489

Published: 2005

NARROW

Light Chain Amyloidosis and Non-Hodgkin's Lymphomas: A Peculiar Association with Distinct Clinical Features and Outcome

Pomalidomide + Bortezomib + Low-Dose Dexamethasone Vs Bortezomib + Low-Dose Dexamethasone As Second-Line Treatment in Patients with Lenalidomide-Pretreated Multiple Myeloma: A Subgroup Analysis of the Phase 3 Optimismm Trial

Bortezomib/Cyclophosphamide/Dexamethasone Versus Lenalidomide/Cyclophosphamide/Dexamethasone in Multiple Myeloma Patients at First Relapse: Final Results of a Phase III Study

Biomarker-Based Screening of Organ Dysfunction in Patients with MGUS Allows Early Diagnosis of AL Amyloidosis

Real Life, Retrospective Analysis of Bortezomib Re-Use As Second Treatment for Relapsed Multiple Myeloma Patients Previously Exposed to Bortezomib-Based Therapies As First Line: The Rebound Study

VD Versus VTD Induction: Similar Efficacy in Controlling Disease in Transplant Eligible Multiple Myeloma Patients Outside Clinical Trials

Impact of Switching from Intravenous to Subcutaneous Bortezomib in Real Life. Overlapping Toxicity and Efficacy in All Settings of Myeloma Patients Balancing Schedule and Way of Bortezomib Adminisration

Analysis of Final Data from the Multinational, Non-Interventional, Observational Emmos Study (NCT01241396) in Patients (Pts) with Multiple Myeloma (MM) in Real-World Clinical Practice

Treated Multiple Myeloma Patients: Demographic Characteristics, Incidence Rate and Mortality in Lombardy during the 2003-2009 Period

High Prevalence Of Extramedullary Relapse In Patients With Multiple Myeloma Treated With Novel Biological Agents

Bendamustine, Low-Dose Dexamethasone, and Lenalidomide (BdL) For The Treatment Of Patients With Relapsed Multiple Myeloma Confirms Very Promising Results In a Phase I/II Study

Physician-Patient Relationship: Intervention Opportunities for Multiple Myeloma patients' Needs

Fotemustine IN COMBINATION with BORTEZOMIB and DEXAMETHASONE: Encouraging PRELIMINARY RESULTS FROM A PHASE II STUDY On Relapsed REFRACTORY MYELOMA PATIENTS

Changing Pattern of Presentation in Monoclonal Gammopathy of Undetermined Significance: A Study on 1400 Cases

Has the Incidence of Extramedullary Disease Changed with the New Therapeutic Approaches? Analysis of a Cohort of 965 Multiple Myeloma (MM) Patients (pts).

Low Efficacy of Thalidomide in Improving Response after Induction in Myeloma Patients Candidate to High-Dose Therapy.

Bisphosphonates and Osteonecrosis of the Jaw: Advantages of a New Schedule.

Modification of Cytokine Levels and CD34+ Stem Cell Adhesion Molecules during Mobilization in Multiple Myeloma (MM) Patients.

High Dose Chemotherapy and Autologous Stem Cell Transplantation in Multiple Myeloma: Comparison of Four Preparative Regimens.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only